Drugs A-Z Is my price fair? Price changes Drug markups Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme

Manufacturer

Alvogen, Inc.

21 drugs, 62 product strengths, 21 recalls on record.

Drugs Alvogen, Inc. makes

Levothyroxine-0.4%Generic · 32 makersPharmacies pay from$1.0659 open recallsSertraline+0.8%Generic · 42 makersPharmacies pay from$0.852 open recallsOseltamivir+0.2%Generic · 32 makersPharmacies pay from$9.33Hydrocodone-0.1%Generic · 1 makerPharmacies pay from$2381 open recallEstradiol-0.5%Generic · 39 makersPharmacies pay from$1.8617 open recallsOxycodone+4.5%Generic · 28 makersPharmacies pay from$2.772 open recallsNaproxen-3.7%Generic · 145 makersPharmacies pay from$1.484 open recallsDexamethasone+3.2%Generic · 59 makersPharmacies pay from$1.19Unavailable10 open recallsTestosterone-3.4%Generic · 29 makersPharmacies pay from$35.2068 open recallsBuprenorphine+0.6%Generic · 26 makersPharmacies pay from$8.626 open recallsAmphetamine aspartate / amphetamine sulfate / dextroamphetamine saccharate / dextroamphetamine sulfate-2.4%Generic · 25 makersPharmacies pay from$6.81Unavailable6 open recallsLisdexamfetamine+6.8%Generic · 18 makersPharmacies pay from$74.56Limited availability8 open recallsNitrofurantoin, macrocrystals / nitrofurantoin, monohydrate-8.1%Generic · 30 makersPharmacies pay from$8.16Buprenorphine / naloxone+8.2%Generic · 22 makersPharmacies pay from$16.17Acetaminophen / oxycodone-0.4%Generic · 23 makersPharmacies pay from$3.532 open recallsPyridostigmine-4.4%Generic · 17 makersPharmacies pay from$7.14Methenamine-0.6%Generic · 17 makersPharmacies pay from$9.33Rasagiline+7.6%Generic · 12 makersPharmacies pay from$13.80Teriparatide-1.4%Generic · 6 makersPharmacies pay from$1,0601 open recallDisulfiram-4.1%Generic · 5 makersPharmacies pay from$52.45Bonsity-1.4%Brand · teriparatidePharmacies pay from$1,060

Recalls

Class IIOngoingJan 21, 2026Levothyroxine Sodium TabletsProduct Mix-Up: A single bottle of this lot was reported by a pharmacy to contain 88 mcg tablets instead of 150 mcg tablets.Alvogen, Inc · D-0259-2026Class IOngoingFeb 26, 2025Fentanyl Transdermal System CIIDefective delivery system - patches could be multi-stacked, adhered one on top of the other, in a single product pouch.Alvogen, Inc · D-0245-2025Class IITerminatedMar 8, 2023Levothyroxine Sodium TabletsSub-Potent Drug: Out of specification for assay at the 24 month interval.Alvogen, Inc · D-0353-2023Class IITerminatedJul 14, 2021Buprenorphine and Naloxone Sublingual Film 2mg/0.5mgSubpotent drug: Out of specification for assay of naloxone and buprenorphine (low)Alvogen, Inc · D-0649-2021Class IITerminatedAug 21, 2019Nitrofurantoin Monohydrate/Macrycrystals CapsulesFailed dissolution specificationsAlvogen, Inc · D-1722-2019Class IITerminatedAug 21, 2019Macrobid Urinary Tract AnitbacterialFailed dissolution specificationsAlvogen, Inc · D-1723-2019Class ITerminatedMay 15, 2019FENTANYL Transdermal SystemProduct Mix-Up: Customer complaint that their carton labeled as Fentanyl Transdermal Systems, 12 mcg/h contained five patches labeled and containing 50 mcg/h.Alvogen, Inc · D-1277-2019Class IITerminatedJul 12, 2017Clindamycin Injection USPLack of Assurance of SterilityAlvogen, Inc · D-0939-2017Class IITerminatedJul 12, 2017Clindamycin Injection USPLack of Assurance of SterilityAlvogen, Inc · D-0940-2017Class IITerminatedJul 12, 2017Clindamycin Injection USPLack of Assurance of SterilityAlvogen, Inc · D-0941-2017Class IIITerminatedApr 12, 2017Nifedipine Extended-Release TabletsCross Contamination with another product:residual powder found in inlet air duct identified as sorafenibAlvogen, Inc · D-0627-2017Class IIITerminatedApr 12, 2017Adalat CCCross Contamination with another product:residual powder found in inlet air duct identified as sorafenibAlvogen, Inc · D-0628-2017Class IIITerminatedApr 12, 2017Adalat CCCross Contamination with another product:residual powder found in inlet air duct identified as sorafenibAlvogen, Inc · D-0629-2017Class IIITerminatedApr 12, 2017Nifedipine Extended-Release TabletsCross Contamination with another product:residual powder found in inlet air duct identified as sorafenibAlvogen, Inc · D-0630-2017Class IIITerminatedApr 12, 2017Nifedipine Extended-Release TabletsCross Contamination with another product:residual powder found in inlet air duct identified as sorafenibAlvogen, Inc · D-0631-2017Class IIITerminatedApr 12, 2017Adalat CCCross Contamination with another product:residual powder found in inlet air duct identified as sorafenibAlvogen, Inc · D-0632-2017Class IIITerminatedApr 12, 2017Adalat CCCross Contamination with another product:residual powder found in inlet air duct identified as sorafenibAlvogen, Inc · D-0633-2017Class IIITerminatedApr 12, 2017Adalat CCCross Contamination with another product:residual powder found in inlet air duct identified as sorafenibAlvogen, Inc · D-0634-2017Class IIITerminatedApr 12, 2017Adalat CCCross Contamination with another product:residual powder found in inlet air duct identified as sorafenibAlvogen, Inc · D-0635-2017Class IITerminatedMay 20, 2015NITROFURANTOIN MONOHYDRATE/MACROCRYSTALS CAPSULESFailed Dissolution Specification; 6 month time pointAlvogen, Inc · D-1082-2015Class IITerminatedOct 1, 2014Oxycodone and Acetaminophen Tablets USP 10 mg/325 mgFailed Content Uniformity Specifications - The lot failed to meet the acceptance criteria for Uniformity of Dosage Units at the time of release for the oxycodone...Alvogen, Inc · D-1607-2014

About Alvogen, Inc.

Be kind and stay on topic. No personal health details, links or selling. This is not medical advice.

No comments yet. Questions, tips, what worked for you - start the conversation.

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.